


Journal Pre-proof

Transcranial magnetic stimulation, deep brain stimulation, and other forms of neuromodulation for substance use disorders: Review of modalities and implications for treatment

James J. Mahoney, Colleen A. Hanlon, Patrick J. Marshalek, Ali R. Rezai, Lothar Krinke



PII: S0022-510X(20)30486-X

DOI: <https://doi.org/10.1016/j.jns.2020.117149>

Reference: JNS 117149

To appear in: *Journal of the Neurological Sciences*

Received date: 20 August 2019

Revised date: 7 September 2020

Accepted date: 18 September 2020

Please cite this article as: J.J. Mahoney, C.A. Hanlon, P.J. Marshalek, et al., Transcranial magnetic stimulation, deep brain stimulation, and other forms of neuromodulation for substance use disorders: Review of modalities and implications for treatment, *Journal of the Neurological Sciences* (2020), <https://doi.org/10.1016/j.jns.2020.117149>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Transcranial Magnetic Stimulation, Deep Brain Stimulation, and Other Forms of Neuromodulation for Substance Use Disorders: Review of Modalities and Implications for Treatment

James J. Mahoney, III, Ph.D.¹, Colleen A. Hanlon, Ph.D.², Patrick J. Marshalek, M.D.¹, Ali R. Rezai, M.D.¹, Lothar Krinke, Ph.D.^{1,3}

¹West Virginia University, School of Medicine and Rockefeller Neuroscience Institute, Department of Behavioral Medicine and Psychiatry, Department of Neuroscience, 930 Chestnut Ridge Road, Morgantown, West Virginia, 26505

²Wake Forest School of Medicine, Cancer Biology and Center for Substance Use and Addiction, 475 Vine Street, Winston-Salem, NC 27101

³Magstim, Inc. 9855 West 78 Street, Suite 12, Eden Prairie, MN, 55344

Corresponding Author:

James J. Mahoney, III, Ph.D.

West Virginia University School of Medicine
Rockefeller Neuroscience Institute

Department of Behavioral Medicine and Psychiatry

Department of Neuroscience

Morgantown, WV, 26505

Email: james.mahoney@hsc.wvu.edu

Phone: (304) 293-1822

Fax: (304) 293-2325

Abstract

Given the high prevalence of individuals diagnosed with substance use disorder, along with the elevated rate of relapse following treatment initiation, investigating novel approaches and new modalities for substance use disorder treatment is of vital importance. One such approach involves neuromodulation which has been used therapeutically for neurological and psychiatric disorders and has demonstrated positive preliminary findings for the treatment of substance use disorder. The following article provides a review of several forms of neuromodulation which warrant consideration as potential treatments for substance use disorder. PubMed, PsycINFO, Ovid MEDLINE, and Web of Science were used to identify published articles and clinicaltrials.gov was used to identify currently ongoing or planned studies. Search criteria for Brain Stimulation included the following terminology: transcranial direct current stimulation, transcranial magnetic stimulation, theta burst stimulation, deep brain stimulation, vagus nerve stimulation, trigeminal nerve stimulation, percutaneous nerve field stimulation, auricular nerve stimulation, and low intensity focused ultrasound. Search criteria for addiction included the following terminology: addiction, substance use disorder, substance-related disorder, cocaine, methamphetamine, amphetamine, alcohol, nicotine, tobacco, smoking, marijuana, cannabis, heroin, opiates, opioids, and hallucinogens. Results revealed that there are currently several forms of neuromodulation, both invasive and non-invasive, which are being investigated for the treatment of substance use disorder. Preliminary findings have demonstrated the potential of these various neuromodulation techniques in improving substance treatment outcomes by reducing those risk factors (e.g. substance craving) associated with relapse. Specifically, transcranial magnetic stimulation has shown the most promise with several well-designed studies supporting the potential for reducing

substance craving. Deep brain stimulation has also shown promise, though lacks well-controlled clinical trials to support its efficacy. Transcranial direct current stimulation has also demonstrated promising results though consistently designed, randomized trials are also needed. There are several other forms of neuromodulation which have not yet been investigated clinically but warrant further investigation given their mechanisms and potential efficacy based on findings from other studied indications. In summary, given promising findings in reducing substance use and craving, neuromodulation may provide a non-pharmacological option as a potential treatment and/or treatment augmentation for substance use disorder. Further research investigating neuromodulation, both alone and in combination with already established substance treatment (e.g. medication treatment), warrants consideration.

Keywords: neuromodulation, substance use disorder, transcranial magnetic stimulation, deep brain stimulation, focused ultrasound, transcranial direct current stimulation, vagus nerve stimulation, trigeminal nerve stimulation, percutaneous nerve field stimulation

1. Introduction

According to the 2018 National Survey on Drug Use and Health (NSDUH), approximately 20.3 million people had a substance use disorder (SUD) diagnosis in 2018¹. Specifically, 14.8 million people met criteria for alcohol use disorder and 8.1 million people met criteria for an illicit SUD, the most common being for marijuana (4.4 million people) and prescription pain relievers (1.7 million people). Over the past several years, the opioid epidemic has plagued our nation and it was estimated that 10.3 million people misused opioids in 2018¹. Opioids are the main contributor to drug overdose deaths, resulting in over 46,800 deaths nationwide in 2018^{1,2}. Further complicating matters is the rate of co-occurring elevated substance use. For example, results from a nationally representative database, which included 356 individuals with OUD, revealed that approximately 57% of individuals with OUD also met criteria for at least one other SUD. Of those co-occurring substance users, approximately 51% reported the use of cannabis, 41% reported the use of sedatives, and 31% reported the use of cocaine or other

stimulants over the past year³. While our nation is clearly facing an opioid epidemic, we must not neglect the potential additive detriment caused by co-occurring opioid and non-opioid substance use and the aversive impact it may have on successful treatment outcomes.

Unfortunately, the number of individuals with SUD far exceeds the number of patients receiving SUD treatment. For example, of the 21.2 million individuals with SUD in 2018, only 3.7 million people received any form of SUD treatment¹. Further complicating matters is the high comorbidity between SUD and other psychiatric disorders. In 2018, an estimated 9.5 million adults (approximately 4% of all adults) had both mental illness and SUD in the past year, and 3.2 million adults had co-occurring *serious* mental illness and SUD¹. Another factor impacting successful treatment is the lack of medication treatments for SUDs, other than medication for nicotine/tobacco, alcohol and opioids. This is especially critical given the rise of other substance use, such as methamphetamine, which was implicated in 35% of overdose deaths in 2017, representing over a 42% increase between 2015 and 2017⁴. While medication has been considered an effective form of treatment in improving outcomes (abstinence, harm reduction) for those SUDs with available medication treatment, effect sizes are relatively modest for alcohol use^{5,6} and smoking cessation⁷ and approximately 50% of those with OUD relapse to opioids and/or other substances even when receiving medication treatment⁸. For example, in a multisite, randomized trial, the rate of unsuccessful outcomes following medication treatment (using buprenorphine-naloxone) exceeded 90% and even when individuals were stabilized on medication over 12 weeks, the rate of successful outcomes was less than 50%⁸. Similarly, extended release naltrexone and buprenorphine have unacceptably high relapse rates (65% vs. 57% respectively)⁹. In addition, a recent review of extended release naltrexone, revealed that many patients never even start the treatment because of difficulty tolerating the withdrawal symptoms and those who start often discontinue¹⁰.

Clearly, new modalities to treat and/or augment SUD treatment are urgently needed and investigating novel approaches is of vital importance. Specifically, non-pharmacological approaches warrant investigation especially for those substances which do not yet have medication treatments

available. In addition, these approaches may provide benefit for those individuals who cannot tolerate medications due to side effects, do not had a positive response to the medication, and/or do not have access to prescribers of those medications. One such approach involves neuromodulation which has been used therapeutically for neurological and psychiatric disorders and has also been used for exploratory purposes in order to research the neurocircuitry of the brain. There are various forms of neuromodulation, some which include non-invasive techniques, such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) with the primary targeted brain regions being the cortical structures of the reward neurocircuitry. Specifically, these regions include the prefrontal cortical network including the dorsolateral prefrontal cortex (DLPFC) and the orbitofrontal cortex^{11,12} which have important functions in inhibitory control, a neurobehavioral output often impaired in patients with SUDs. Reduced inhibitory control and disinhibition are also associated with relapse susceptibility¹³⁻¹⁷. Furthermore, the DLPFC and its surrounding network are also associated with substance craving, a major clinical feature of SUD associated with poor treatment outcome and relapse. In addition, some forms of neuromodulation, such as TMS, have demonstrated benefit in reducing symptoms of co-occurring psychiatric disorders/symptoms (e.g. depression) which may be further perpetuating and/or exacerbating an individual's SUD.

Other forms of neuromodulation involve invasive techniques, such as deep brain stimulation (DBS), which provides the ability to target subcortical structures. The primary subcortical brain target is the nucleus accumbens (NAc) which is considered the center of the reward circuitry and heavily implicated in substance use and craving¹⁸⁻²². In addition to the prefrontal cortical network, the NAc also maintains direct and indirect involvement with several brain regions, such as the dorsal striatum, amygdala, hippocampus, areas which are associated with emotions, self-regulation, disinhibition, insight, craving, and habit forming¹⁹. While not yet approved for the treatment of SUD, these forms of neuromodulation mentioned have demonstrated promising preliminary results in reducing substance use and craving. There are additional forms of neuromodulation which have not yet been thoroughly

investigated for the treatment of SUD, including focused ultrasound (FUS) and vagus (VNS) and trigeminal nerve stimulation (TNS) along with percutaneous nerve field stimulation (PNFS), the latter which has been approved for opioid withdrawal. The following article will provide a brief review of several forms of neuromodulation which are either currently being investigated for SUD or warrant consideration as a potential treatment based on their targeting capabilities and findings involving other indications. A general overview of these forms of neuromodulation is displayed in **Table 1** and details specific to the potential treatment of substance use disorder can be found in **Table 2**.

Table 1: General Overview of Potential Forms of Neuromodulation for the Treatment of SUD

Neuromodulatory Technique	Invasive/ Non-Invasive	Target Depth	Focal	FDA Approved Indications	Adverse Events	Patient Acceptability
Transcranial Magnetic Stimulation (TMS)	Non-Invasive	Cortical	No	Depression, OCD	Temporary pain, muscle twitch, very low seizure risk	Some forms (rTMS) require daily visits to a clinic for several weeks (though continuous theta burst stimulation treatment requires less treatment frequency/length).
Low Intensity Focused Ultrasound (LIFU)	Non-Invasive	Subcortical	Yes	Essential Tremor, Parkinson's	Limited, theoretical risk of ICH	Perceived as non-invasive by patients
Deep Brain Stimulation (DBS)	Highly Invasive	Subcortical	Yes	Parkinson's, Essential Tremor, Dystonia, Epilepsy, OCD	Brain implant related side effects: pain, ICH, infection	Patient's concern regarding brain implant and managing an implanted device
Transcranial Direct Current Stimulation (tDCS)	Non-Invasive	Cortical	No	None	Few side effects	Patients can self-manage at home
Vagus Nerve Stimulation (VNS)	Invasive (Implantable VNS)	Direct Nerve Stimulation	Yes	Depression, Epilepsy	Difficulty swallowing, vocal changes, shortness of breath	Patient's concern regarding implant and managing an implanted device
Auricular Nerve Stimulator/ Percutaneous Nerve Field Stimulation (PNFS)	Minimally Invasive/ Non-Invasive	Direct Nerve Stimulation	No	Symptoms of Opioid withdrawal	Bleeding, pain, dermatitis	Minimally invasive wearable device, viewed as more acceptable by patients
Trigeminal Nerve Stimulation (TNS)	Non-invasive (eTNS)	Direct Nerve Stimulation	Yes	Pediatric ADHD	Drowsiness, increased appetite, sleep dysfunction, teeth clenching, headache, fatigue	Patient acceptability due to non-invasiveness

Table 2: Applicability of Neuromodulation for the Treatment of SUD

Neuromodulatory Technique¹	SUD Research	Region of Interest or Brain Target	Evidence Level
Transcranial Magnetic Stimulation (TMS)	Alcohol, cocaine, methamphetamine, opioid, cannabis, nicotine	DLPFC, Medial Prefrontal cortex, ACC	Multiple clinical trials, associated with reductions in substance craving and use
Low Intensity Focused Ultrasound (LIFU)	None	NAc	No published pre-clinical or clinical investigations
Deep Brain Stimulation (DBS)	Alcohol, heroin, nicotine	NAc	Multiple case reports, pre-clinical data, associated with reductions in substance craving and use
Transcranial Direct Current Stimulation (tDCS)	Alcohol, cocaine, cannabis, nicotine	DLPFC	Multiple clinical trials, associated with reductions in substance craving and use though inconsistent evidence for efficacy, likely due to varying study designs
Vagus Nerve Stimulation (VNS)	Pre-clinical only	Vagus nerve	Changes in cortical excitability, extinguishing responses to drug-associated environmental stimuli
Auricular Nerve Stimulation/ Percutaneous Nerve Field Stimulation (PNFS)	Opioid Withdrawal	Percutaneous Nerve Field	One open label trial
Trigeminal Nerve Stimulation (TNS)	None	Trigeminal Nerve	No published pre-clinical or clinical investigations

¹None of the above mentioned methods of neuromodulation have received FDA approval for SUD (with the exception of PNFS which received De novo 510(k) clearance for SUD) and none have been approved for insurance reimbursement.


2. Potential Forms of Neuromodulation for Substance Use Disorder Treatment

The number of original research publications indexed on PubMed from 1999-2018 which involved brain stimulation and substance use is displayed in **Figure 1**. PubMed search criteria for Brain Stimulation included MESH indexing related to “transcranial direct current stimulation”, “transcranial magnetic stimulation”, “theta burst stimulation”, “deep brain stimulation”, “vagus nerve stimulation”, “trigeminal nerve stimulation”, “percutaneous nerve field stimulation”, “auricular nerve stimulation”, and “low intensity focused ultrasound.” Addiction terms included MESH indexing related to “addiction”, “substance use disorder”, “substance-related disorder”, “cocaine”, “methamphetamine”, “amphetamine”, “alcohol”, “nicotine”, “tobacco”, “smoking”, “marijuana”, “cannabis”, “benzodiazepines”, “heroin”, “opiates”, “opioids”, and “hallucinogens”. The search was limited to articles involving human subjects and original research (e.g. clinical trials, clinical or observational studies, or case reports); reviews, meta-analyses, and editorials were excluded. Of the 22,098 entries that met criteria for Brain Stimulation, and the 139,236 that met criteria for Addiction, there were 188 that met criteria for both (blue bars) and of those, 106 included a form of TMS (red bars). This highlights that as the field is growing exponentially, the variance in techniques is also changing as TMS accounted for 78% of the publications from 1999-2008, whereas 46% of the publications utilized techniques other than TMS from 2009-2019.

While Figure 1 includes original research publications indexed on PubMed, in order to conduct a more inclusive search for this review, other electronic databases including PsycINFO, Ovid MEDLINE, and Web of Science were also included using the same search terminology mentioned above. Only those which were published in (or were translated into) English were included in the broader search. In addition, while reviews, editorials, and meta-analyses were excluded from the search referenced in Figure 1 (in order to avoid duplication and only include those publications which contain original research), these forms of publication were included in the broader search, along with relevant references contained within those publications. Also, for those forms of neuromodulation which lack clinical

literature related to SUD (e.g. LIFU, TNS, VNS), a search of clinicaltrials.gov was performed using the terminology mentioned above to gauge current, planned, or upcoming investigations.

Figure 1 - 20 years of Research on Human Brain Stimulation in Addiction-Related Disorders



2.1. Transcranial Magnetic Stimulation (TMS)

Within interventional psychiatry, one of the most active new areas of research has been the development of TMS as a non-invasive tool to stimulate neural circuits typically involved in psychiatric disease. TMS is a non-invasive form of brain stimulation which induces a hyperpolarization or depolarization (dependent on delivered frequency as described below) of neurons through electromagnetic induction. Although a comprehensive review of studies that have demonstrated these principles of TMS is beyond the scope of this manuscript, prior behavioral, electrophysiological, and neuroimaging work in this area is well described and summarized in several review articles^{23,24}.

TMS has been FDA-approved as a treatment for major depressive disorder since 2008 and received FDA-approval for the treatment of obsessive compulsive disorder in 2018. There are now TMS clinics in all 50 states in the United States, throughout Europe, Asia, Australia, South America, and a

few new clinics in Africa. While the majority of the research in TMS is focused on optimizing treatment protocols for depression, there has been an exponential growth in the application of TMS to investigate and modulate these networks in populations with SUDs including alcohol, cocaine, methamphetamine, opioid, cannabis, and nicotine use^{11,12,25-29}. There are four key principles of TMS that are necessary to understand before interpreting the results of current studies and designing novel interventions for alcohol and SUDs:

Stimulation Depth. With a growing number of TMS coil designs, this is an increasingly complex question to answer. The focality of TMS is related to the shape of the coil and there is substantial body of literature devoted to computational modeling of electric field distributions associated with different coil shapes. In one of the most comprehensive papers, Deng and colleagues (2013) investigated the focality and penetration depth of 50 existing TMS coils³⁰. Their computational models revealed that typical figure-of-8 coil designs affected approximately 10 cm² of cortical surface, circular coils affected approximately 50cm², and H-coil designs affected approximately 100 cm². Most flat figure-of-eight and circular coil designs had penetration depths from 1-2cm², whereas the H-coil designs had consistently higher depths of 2-3cm. The H-coil was designed to affect the neuronal pathways and fibers to deeper cortical regions in order to facilitate targeting subcortical regions (without significantly impacting the electric fields in cortical regions)³¹. While TMS was originally unable to target the deeper, subcortical structures involved in the reward circuitry, given the rich interconnectivity between the prefrontal cortex (PFC) and subcortical limbic and reward system structures³²⁻³⁵, these regions are able to be indirectly impacted by the cortical stimulation, somewhat alleviating the limitation of reduced depth. However, it is well established that chronic drug use (specifically chronic alcohol use) leads to cortical atrophy³⁶ which suggests that a higher stimulation intensity or a bent coil may be more likely to reach the cortex of these individuals.

Polysynaptic Transmission. Beyond the direct cortical effects of TMS, it is possible to modulate monosynaptic (and possibly polysynaptic) targets of these cortical areas. When this depolarizing

current is strong enough, however, it leads to a cascade of neurotransmitter release, excitatory postsynaptic potentials, and eventually action potentials in neurons receiving monosynaptic inputs from the neurons depolarized by the TMS pulse. This has been documented using interleaved TMS/BOLD imaging wherein a single pulse of TMS induces an elevation in the BOLD signal in the vicinity of the TMS coil and in monosynaptic target regions^{37,38}. In this manner, cortical pulses of TMS can be used to investigate frontal-striatal connectivity, as the dorsal and ventral striatum both receive monosynaptic inputs from the frontal cortex. The dorsal and ventral frontal-striatal circuits are topographically organized and modulate the executive control and limbic arousal aspects of the addiction and relapse cycle, respectively.

Frequency dependent modulation. As stated above, when single pulses of TMS are delivered in rapid succession (rTMS), it is possible to change cortical excitability and various behavioral phenomena for a relatively brief period of time (e.g. 30 minutes to several hours). These effects appear to be frequency dependent, wherein low frequency, continuous stimulation decreases cortical excitability wherein high frequency, intermittent stimulation leads to an increase in cortical excitability^{39,40}. These LTD-like and LTP-like effects for repetitive TMS can also be achieved through theta burst stimulation (TBS). In preclinical literature, TBS is a well-known form of electrical stimulation which can induce long-term potentiation or depression of synaptic activity in a given brain region⁴¹. Human TBS protocols use rTMS to induce similar forms of LTP and LTD by using intermittent or continuous bursts respectively⁴². With continuous TBS (cTBS), bursts of three pulses at 50 Hz are applied at a frequency of 5 Hz at an amplitude that is typically determined by the active motor threshold. By uniting this principle with the others, it is logical to conclude that there are at least two potential neural-circuit based strategies for improving outcomes in substance users: decreasing activity in the ventral-medial, frontal-striatal circuit with LTD-like TMS or increasing activity in the dorsal-lateral, frontal-striatal circuit with LTP-like TMS. Practically speaking, an advantage of TBS is the length of the individual treatment sessions, which can be completed over 3 minutes, opposed

to TMS, which can last approximately 40 minutes per session. Moreover, the reduced treatment length of TBS is not at the expense of clinical effectiveness. In a randomized, multicenter, clinical trial in patients with depression, intermittent TBS was found to be non-inferior to traditional TMS with regard to outcomes, side-effects, safety, and tolerability⁴³.

State-dependent effects. An emerging body of literature is demonstrating that behavioral priming before or during the TMS administration has a significant impact on the amplitude and possibly directionality of the TMS effects on the brain and behavior⁴⁴. In fact, recent FDA-approval of TMS for treatment of OCD requires that the patient be exposed to a specific, anxiety-provoking stimulus during the treatment visit. The amplifying influence of cue-exposure on TMS treatment outcome was also demonstrated in a study of post-traumatic stress disorder (PTSD)⁴⁵. A large clinical trial of TMS for smoking cessation demonstrated that the effects of TMS are amplified when an individual is exposed to a smoking cue during TMS delivery⁴⁶. In this prospective, double-blind, sham-controlled study, 115 regular cigarette smokers were randomized to receive 10 daily treatments of TMS. Immediately before each session, half of the participants were presented with visual smoking cues. There was reduced cigarette consumption and nicotine dependence, and the effects were greatest in the individuals that were exposed to smoking cues⁴⁶.

A complete review of the existing literature on TMS applied to SUDs can be found in recent review articles^{47,48}. Most of the rTMS studies to date have applied an LTP-inducing form of TMS to the DLPFC in an effort to decrease craving¹⁷. This area has an important role in executive and inhibitory control, often impaired in patients with SUDs, and disinhibition is also associated with relapse¹³⁻¹⁷. At the current time, it is not entirely clear why increasing activity in the DLPFC (an element in the executive control network) would decrease craving (a function typically ascribed to the ventral medial PFC and ventral subcortical areas). A recent study, however, demonstrated that, within healthy controls, there is a reciprocal relationship between DLPFC stimulation and subsequent attenuation of Brodmann 10 in the MPFC, but this is not present in the cocaine users⁴⁹. These data build upon studies in patients

with depression^{39,50} and provide a biological mechanism through which DLPFC may be effective at attenuating craving. An alternative TMS treatment strategy that has shown promise is the application of LTD-like TMS directly to the ventral MPFC^{51,52}.

As described above, the largest TMS study in addiction to date was performed by Dinur-Klein and colleagues (2014)⁴⁶ wherein they demonstrated that TMS delivered to the left DLPFC reduced cigarette consumption for 3 months. There are now over 20 published manuscripts evaluating TMS as a method to decrease smoking and smoking related behaviors. There are also several relatively large published trials which have evaluated TMS as a tool to decrease alcohol⁵³ and cocaine use⁵⁴. There is only one published study on the use of rTMS for opioid use disorder, which demonstrated that a single session of rTMS to the left DLPFC reduced cue-induced craving⁵⁵, however, given the ongoing opioid crisis in many parts of the world, this area of research maintains positive momentum as a potential treatment for OUD.

In summary, there is currently a growing body of literature which suggests it is possible to induce circuit-specific and frequency dependent effects on dopamine, glucose, and neural activity (measured through functional neuroimaging) through the administration of rTMS. The conceptual framework for designing TMS treatment strategies in alcohol and substance use research is well described in a recent consensus paper published by over 50 scientists in this area⁴⁸. This form of neuromodulation is actively being investigated as a new therapeutic agent in a number of clinical trials in individuals with cocaine, nicotine, alcohol, and methamphetamine use disorders. That being said, the optimal cortical location to target in substance users is unclear and many of the current investigations in SUD are based on the parameters used for depression rather than evidence from addiction literature. Fortunately, there are decades of functional neuroimaging research in cocaine users that can serve as “maps” for optimal TMS target selection. By harnessing the knowledge we have acquired from functional neuroimaging studies, it may be possible to develop TMS as an evidence-based, translationally-grounded therapeutic treatment for SUD.

2.2. Focused Ultrasound (FUS)

Transcranial focused ultrasound (FUS) is a non-invasive technique which has the capability to precisely target subcortical brain structures and modulate neural circuitry^{56,57}. There are two major modalities of FUS: High Intensity Focused Ultrasound (HIFU) and Low Intensity Focused Ultrasound (LIFU). HIFU creates permanent lesions through coagulation of cellular proteins and thermal ablation⁵⁸ and is FDA approved for the treatment of tremor associated with Parkinson's disease⁵⁹ and essential tremor^{60,61}. HIFU is also emerging as a viable treatment option for chronic pain⁶² and the effects of HIFU treatment in pain reduction are relative rapid (within a day of sonication) in patients refractory to treatment with more traditional methods, exhibiting benefit one year after treatment. In addition, patients treated with HIFU also evidenced marked reductions in opioid intake following the sonication of painful lesions⁶³.

Unlike the permanent lesions/ablation caused by HIFU, LIFU is considered an emerging form of non-invasive neuromodulation as it creates reversible functional lesions that produce no pathological changes on histological examination⁵⁶. While the main mechanism behind HIFU is rapid heating of targeted tissue for ablation, LIFU is delivered in a pulse mode with less intensity which minimizes the probability of tissue heating or damage. LIFU is unique among neuromodulatory methods in that it not only has exceptional spatial resolution⁶⁴⁻⁶⁶ but also has the capability of targeting deeper, subcortical structures⁶⁷. In a recent study conducted in patients with Alzheimer's disease, the application of LIFU, coupled with injected microbubbles, transiently opened the blood brain barrier in a targeted, noninvasive, safe, and reversible manner⁶⁸. This demonstrates the potential application for targeted neuromodulation and/or medication delivery for those therapies which would otherwise be unable to cross the blood brain barrier⁵⁶.

Given the known cognitive dysfunction present in individuals with SUD, LIFU also has the potential to possibly remediate these cognitive deficits. For example, fMRI findings following LIFU sonication of the human primary visual cortex demonstrated that the sonication effects expanded to remote areas in the brain outside of the primary visual circuits. Specifically, LIFU increased neural activity at the level of brain networks involved in higher-order visual and cognitive processing, regions which included the frontal-temporal-parietal areas and cerebellum (the attention networks involved in cognitive processing) and the parahippocampal gyrus and thalamus (the memory/navigation/recognition networks)⁶⁹. While, to the best of our knowledge, LIFU as a potential treatment for SUD has not yet been investigated, this form of neuromodulation warrants consideration. For example, LIFU has the potential to provide results of greater magnitude than other forms of neuromodulation given the exceptional spatial resolution and ability to target deeper, subcortical structures such as the NAc.

2.3. Deep Brain Stimulation (DBS)

Deep brain stimulation (DBS) is a surgical procedure in which bipolar electrodes are placed into specific brain regions and stimulated through implanted pulse generators⁷⁰. Stimulation parameters are programmable and depend on targeted brain region, disorder, and patient response. DBS is an FDA approved treatment for patients with Parkinson's disease, essential tremor, dystonia and OCD (under a Humanitarian Device Exemption [HDE]), and most recently, treatment refractory epilepsy. Several clinical investigations have explored the utility of DBS to treat a range of neurobehavioral disorders including OCD, depression, Tourette's disease, eating disorders, traumatic brain injury, and Alzheimer's disease⁷¹⁻⁸⁶. DBS for pain reduction has demonstrated favorable results when other methods, such as medications have not been successful. Various chronic pain conditions which respond to DBS include failed back surgery syndrome, phantom limb pain, and peripheral neuropathic pain with a higher response rate for those with nociceptive pain compared to neuropathic pain⁸⁷.

DBS has not been investigated extensively in addiction, though there have been reports of the potential utility of this form of treatment. In humans, case studies have reported that stimulation to the ventral striatum/nucleus accumbens reduced the consumption of substances of abuse, such as alcohol, nicotine, and heroin¹⁴. In one report, an individual who underwent the NAc DBS procedure abstained from heroin use during active DBS for the first 2.5 years and remained drug free for 3.5 years following DBS removal without relapse at a 6-year follow-up. Notable improvements of the subjects' memory, IQ, and emotional status were also observed⁸⁸. In a separate case study two individuals with treatment refractory heroin use disorder achieved complete heroin abstinence at 2-year follow-up with the exception of one single incident of heroin consumption in the weeks following surgery. These individuals reported that their isolated use was solely motivated by "mere curiosity" yet was not reinforcing and did not reinstate chronic heroin use⁸⁷. In a study of five participants with treatment-resistant alcohol use disorder who received DBS of the NAc, all reported a complete absence of craving for alcohol up to 8 years following DBS implantation; two patients remained abstinent for several years, and three showed a marked reduction of alcohol consumption⁹⁰. Another case study reported that DBS of the NAc reduced symptoms related to OCD, which may serve as additional support given the compulsive nature of some drug-taking behavior^{73,91-93}. Interestingly, one of these studies found that DBS targeting the NAc resulted in an unintended and "effortless" smoking cessation⁹⁴.

2.4. Transcranial Direct Current Stimulation (tDCS)

Transcranial direct current stimulation (tDCS) is a non-invasive form of neuromodulation where low-amplitude direct currents are applied directly to the scalp via electrodes. tDCS can be applied unihemispherically or bihemispherically, targeting dual stimulation to two parallel brain regions^{95,96}. Anodal tDCS involves the depolarization of neurons, subsequently increasing cortical excitability, while cathodal tDCS involves the hyperpolarization of neurons, subsequently decreasing cortical excitability⁹⁷. Currently, tDCS is not FDA approved for any indications though trials have demonstrated potential efficacy in the treatment of depression⁹⁸, anxiety⁹⁹, and other psychiatric disorders¹⁰⁰. While there have

been inconsistent findings related to the efficacy of tDCS for the treatment of SUD¹⁰¹, further investigation is warranted with particular emphasis on methodological approaches and long term outcomes. For example, while the inconsistency and variability noted in previous studies can be due to several factors, varying study designs (e.g. duration, length, intensity, and location target of treatment) are likely a primary factor contributing to these discrepancies. For example, given that 20 or more tDCS sessions have been found necessary to achieve clinically significant changes, the reduced number of tDCS sessions delivered in some studies likely contributes to those reports which noted a lack of or non-significant effect of the treatment¹⁰². Also, many studies provide insufficient power due to small sample sizes^{103,104}. Regardless, tDCS continues to be explored for the treatment of psychiatric disorders and novel approaches are being used to increase efficacy, for example, the combination of tDCS stimulation with cognitive tasks¹⁰⁵.

There remains potential applicability of tDCS in treating SUD and the therapeutic effects are conceptualized as secondary to a disruption of the reward networks between the prefrontal regions¹⁰⁵. While there has been inconsistency noted in the results of tDCS for SUD, methodological limitations, such as those noted above, may have contributed to those negative findings. Regardless, some studies have demonstrated positive findings even after shorter durations of treatment. Anodal tDCS to both the right and left DLPFC has been shown to reduce cue-induced nicotine craving and smoking behavior^{106,107}. In addition, when used in combination, both left cathodal/right anodal and left anodal/right cathodal reduced alcohol craving when compared to sham tDCS¹⁰⁸. Anodal tDCS targeting the left DLPFC reduced cue-induced alcohol craving and emotional symptoms (e.g. anxiety, depression) when compared to sham; however, this form of treatment was associated with a trend toward greater relapse in treatment seeking individuals¹⁰⁹. In cocaine users, five sessions of tDCS to the DLPFC (left cathodal/right anodal) significantly reduced cocaine craving when compared to sham¹¹⁰. In cannabis users, right anodal/left cathodal applied to the DLPFC reduced cannabis craving compared to sham stimulation¹¹¹. Also, given the known cognitive deficits associated with SUD, tDCS may also be a

mechanism for improving cognitive dysfunction as studies have demonstrated that tDCS can modify behavior, improve learning, and improve inhibition^{96,112,113}.

2.5. Vagus Nerve Stimulation, Percutaneous Nerve Field Stimulation, and Trigeminal Nerve Stimulation

Stimulating afferent sensory nerves, nerve fibers in the spinal cord, autonomous nerves, and/or cranial nerves, are additional potential methods for modulating brain networks. For example, transcutaneous nerve stimulation and spinal cord stimulation are methods to treat pain¹¹⁴. Vagus nerve stimulation (VNS) is a neuromodulation therapy that is FDA approved as adjunctive therapy for the treatment of epileptic seizures in patients that are refractory to antiepileptic medications. VNS is also FDA approved for the adjunctive long-term treatment of chronic or recurrent depression in patients suffering from major depressive episodes that are refractory to antidepressant treatments. The VNS system is indicated for use in stimulating the left vagus nerve in the neck area inside the carotid sheath and involves the placement of a percutaneous cuff electrode that delivers electric pulses generated by an implantable pulse generator¹¹⁵. More recently, transcutaneous VNS has been investigated for a variety of indications, including epilepsy¹¹⁶ and an external transcutaneous VNS system is approved for the treatment of migraine and cluster headache¹¹⁷. The mechanism of action of VNS has not been fully elucidated but is thought to involve connections to the brainstem resulting in brain network changes, including modulation of cortical excitability and induction of synaptic plasticity¹¹⁸.

One strategy for reducing relapse in addiction is to promote self-regulation by extinguishing responses to drug-associated environmental stimuli. VNS inhibits heroin-seeking behavior induced by heroin priming or heroin-associated cues in rats¹¹⁹ and also reduces cocaine seeking and alters plasticity in the extinction network in rats¹²⁰. The data suggests that VNS reduces reinstatement by the facilitation of extinction. Connections between the PFC and the basolateral amygdala may contribute to the

beneficial effects observed. Translation of these pre-clinical findings suggest that VNS for the treatment of SUD warrants investigation in humans. To the best of our knowledge, no human clinical trials involving VNS for the treatment of addiction have been published to date nor listed on the clinical trials listing site Clinicaltrials.gov.

Minimally invasive and non-invasive auricular nerve stimulation has been studied extensively in several indications including depression, epilepsy, stroke and other neurological disorders¹²¹. The auricular nerve is a branch of the vagus nerve and transcutaneous auricular vagus nerve stimulation (taVNS) is thought to mediate its effect via afferent pathways to brain. A recent meta-analysis revealed the taVNS reduced Hamilton Depression Rating scale ratings and self-reported depression when compared to sham intervention¹²². Previous findings have also demonstrated that taVNS produces changes in resting-state functional connectivity distributed throughout several neural networks involved in addiction, including the default mode, salience and executive networks¹²³. As such, exploring taVNS for the treatment of SUD warrants consideration.

A specific form of auricular nerve stimulation is also referred to as Percutaneous Nerve Field Stimulation (PNFS) which involves branches of the Cranial Nerves V, VII, IX and X and the occipital nerves. PNFS is an FDA approved therapy as an aid to reduce the symptoms of opioid withdrawal¹²⁴. This therapy involves the placement of a percutaneous nerve field stimulator, a multi-pin wire harness percutaneous electrode array and a pen light for use in the transillumination technique that aids in the positioning of the percutaneous electrodes. The FDA clearance was based on a single-arm, open label, multi-center retrospective study of 73 patients measuring reduction in Clinical Opioid Withdrawal Score (COWS) where the mean COWS score was reduced by 62.7% twenty minutes after initiation of therapy. Five days following treatment, 33 patients returned to clinic and the mean withdrawal score reduction was 97.1%¹²⁵. While these results are promising, this trial was not controlled and conducted retrospectively, therefore, prospective and controlled clinical trials should be conducted to establish efficacy.

Trigeminal Nerve Stimulation (TNS) has recently been approved for the treatment of attention deficit and hyperactivity disorder (ADHD). An external TNS System, is indicated for patients ages 7 to 12 years old who are not currently taking prescription ADHD medication¹²⁶. In a clinical trial ADHD-RS total scores showed significant group-by-time interactions. CGI-Improvement scores also favored active treatment¹²⁷. TNS has been studied in a variety of disorders including pain¹²⁸, epilepsy¹²⁹, and depression¹³⁰. While not yet investigated for the treatment of SUD, the non-invasive TNS warrants consideration.

3. Discussion

Given the high prevalence of individuals diagnosed with SUD, along with the elevated rate of attrition and relapse following treatment initiation, investigating novel approaches and new modalities to treat and/or augment SUD treatment is of vital importance. Both invasive and non-invasive methods of neuromodulation have shown promise in the treatment of psychiatric disorders including SUD. There are notable differences when considering these different methods of neuromodulation discussed above as potential treatments for SUD. An obvious difference is the non-invasive nature of some forms, such as TMS, tDCS, and LIFU versus the invasive nature of DBS and nerve stimulation (e.g. VNS). While non-invasive methods are generally preferable for numerous reasons, there are limitations to consider. For example, non-invasive techniques, such as TMS and tDCS, have low spatial resolution, lack specificity, and are limited to superficial target points preventing the application to deeper subcortical targets such as the NAc.

Differences between these non-invasive forms are also present as tDCS has poor spatial and temporal resolution, whereas TMS has higher focality and temporal resolution (milliseconds) and is less sensitive to anatomical differences (e.g. skull thickness). DBS overcomes these limitations through deep, subcortical targeting with greater precision; however, requires an invasive brain surgery and implantation of hardware, which often require replacement of pulse generator (battery), and associated

complications of the implanted hardware. While not yet investigated for SUD, LIFU has the potential to overcome these limitations above by utilizing a preferred non-invasive approach though having the capability to precisely target relatively smaller, subcortical brain regions. In addition to LIFU, there are other methods of neuromodulation not previously mentioned which have not yet been thoroughly investigated for SUD. For example, brain photobiomodulation (PBM) therapy, which uses red to near-infrared light, is an innovative treatment for a wide range of neurological and psychological conditions including depression and anxiety^{131,132} and there is also preclinical evidence of improvement in cognitive decline^{133,134}. While the literature related to PDM for SUD is limited, laser irradiation to auricular acupoints of patients with alcohol use disorder reduced depression and symptoms accompanying alcohol withdrawal¹³⁵.

Neuromodulation technologies have the potential to play a valuable role in assisting patients in several phases of recovery and preventing relapse. For example, while neuromodulation may be helpful during the initial phase of treatment, if symptoms (e.g. craving) begin to re-emerge after sustained abstinence, maintenance therapy should be considered as this form of therapy (specifically TMS) has demonstrated benefit in other populations when symptoms, such as depression, re-emerge after a period of remission. During the early stages of SUD treatment, one of the primary goals is to maintain patient engagement, prevent attrition or discharge against medical advice, and begin to foster the adaptation of coping mechanisms rather than substance use for dealing with distress. Emotional symptoms, substance craving, psychosocial distress, cognitive difficulties, and sleep dysfunction are some of the many inner-related factors and comorbidities which contribute to treatment drop out and relapse further supporting neuromodulation as a stand-alone or adjunctive treatment for SUD given the demonstrated effectiveness in treating these comorbidities.

One of the primary factors contributing to relapse is substance craving^{136,137} and, mechanistically, one conceptualization is that neuromodulation may be effective in extinguishing the learned response to the reinforcing effects to substance, cues, or other triggers. That being said, while

findings have suggested that various forms of neuromodulation can reduce or suppress craving, prior literature has stated that the reduction of craving is necessary but not sufficient for achieving and maintaining abstinence from an addictive substance or behavior¹³⁸. Given that most of the research investigating neuromodulation for SUD has involved Phase I studies with the primary outcome of craving, future research should also focus on the outcome of direct clinical relevance – actual substance use. The exception to this includes studies of nicotine/tobacco which have demonstrated that neuromodulation (e.g. TMS, tDCS) can reduce both craving as well as smoking behavior and/or tobacco use¹³⁹.

Other factors which detrimentally impact treatment outcomes and contribute to treatment attrition and relapse include depression, anhedonia, hopelessness, reduced interest/motivation, and anxiety. As mentioned previously, there is a very high co-morbidity between SUD and other psychiatric disorders¹ and differentiating whether these symptoms are resultant from or exacerbated by ongoing substance use or precipitated substance use is often challenging. Regardless of whether psychiatric symptoms predated substance use or are secondary to ongoing substance use, patients remain at increased risk of relapse if these symptoms and conditions are not appropriately managed. Given that TMS is FDA approved for the treatment of depression and has also been utilized to treat anxiety, it is certainly plausible that implementing this form of neuromodulation for the treatment of SUD will also reduce these co-occurring symptoms which interfere with successful treatment. In other words, treating these symptoms in parallel may lead to improved treatment adherence and engagement and better patient experiences overall subsequently leading to improved outcomes (sustained abstinence). Additionally, if one assumes the same degree of treatment resistance to SUD treatment that is found across other psychiatric conditions, it is equally likely that several failed medication trials will have similar diminishing returns. While controlled substances are commonly utilized in psychiatry for a variety of co-occurring conditions, these medications (e.g. sedatives, stimulants) may have unfavorable risk-benefit profiles for those with SUD. As such, given the limited pharmacotherapeutic options, non-

pharmacological interventions such as neuromodulation warrant consideration, especially in those treatment resistant individuals.

While neuromodulation alone has demonstrated positive effects in reducing substance use and those risk factors associated with relapse, perhaps the best approach would be to evaluate the effectiveness of neuromodulation as an adjunctive treatment to already established behavioral and/or pharmacological treatments for SUD (rather than as a stand-alone treatment). For example, by using neuromodulation to improve the altered reward circuitry in those with SUD, those individuals will then be more likely to comply and engage in with other forms of SUD treatment thus resulting in a higher probability of remaining abstinent. The importance of investigating neuromodulation in combination with behavioral and/or medication treatments has been acknowledged previously^{138,140}, though the literature integrating neuromodulation with psychosocial and pharmacological interventions is currently lacking. Recent case studies however have described the potential usefulness for combining neuromodulation with comprehensive SUD treatment^{141,142}. For example, a case report was recently published investigating TMS in combination with comprehensive SUD treatment which included buprenorphine/naloxone, individual and group therapy, and attendance of social support groups (e.g. AA/NA) within the community. In this case, an individual with treatment refractory cocaine and heroin use disorder demonstrated ~70-82% reductions in craving for these substances following seven sessions of TMS. This individual also remained entirely abstinent from all substances and was fully engaged in his comprehensive SUD treatment for approximately one month following the final TMS session, a considerable improvement as he had previously only been to sustain abstinence for no longer than a few days prior receiving TMS¹⁴¹. In a separate case report involving DBS of the nucleus accumbens/ventral capsule for polysubstance use disorder, an individual with treatment refractory benzodiazepine and opioid use disorder demonstrated complete abstinence, significant decreases in craving, and remained fully engaged in comprehensive SUD treatment at 12 and 24 week outpatient assessments¹⁴². While the findings from these cases must be replicated in a larger cohort of individuals in randomized, controlled

trials, these results are promising in the potential utility of neuromodulation as an adjunctive strategy to augment comprehensive SUD treatment.

4. Conclusions

Investigating novel modalities for the treatment of SUD treatment is of vital importance given the high prevalence of individuals diagnosed with SUD in combination with the elevated rate of attrition and relapse following treatment initiation. Neuromodulation warrants consideration as a potential treatment for SUD given promising findings in reducing substance use and craving in individuals with SUD. Currently, there are several forms of neuromodulation, both invasive and non-invasive, which are being investigated for the treatment of SUD. Further research investigating neuromodulation, both alone and in combination with already established SUD psychosocial and medication treatment, warrants consideration in those seeking treatment for SUD. While neuromodulation has demonstrated some promising results thusfar for the treatment of SUD, more extensive clinical data, subsequent regulatory approvals, and more favorable medical coverage policies will be needed in order to successfully implement this form of treatment to overcome the current substance use crisis our nation is facing.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Dr. Mahoney receives support by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number U54GM104942. Dr. Hanlon receives support by the National Institute of Drug Abuse of the National Institutes of Health under Award Numbers R01DA044471 and R21DA044503. The funding source had no other role other than financial support. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Declaration of Interest

Co-author (Lothar Krinke, Ph.D.) of this publication is Chief Executive Officer of Magstim, Inc., (a TMS system manufacturer) and has also been the General Manager of Deep Brain Stimulation at Medtronic, Inc. No other coauthors have any disclosures.

References

1. Center for Behavioral Health Statistics and Quality. 2018 National Survey on Drug Use and Health: Detailed tables. Rockville MD. 2019.
2. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017. *MMWR Morb Mortal Wkly Rep* 2019;67:1419-1427.
3. Hassan AN, Le Foll B. Polydrug use disorders in individuals with opioid use disorder. *Drug Alcohol Depend.* 2019;198:28-33.
4. Kariisa M, Scholl L, Wilson N, Seth P, Hoots B. Drug Overdose Deaths Involving Cocaine and Psychostimulants with Abuse Potential - United States, 2003-2017. *MMWR Morb Mortal Wkly Rep.* 2019;68(17):388-395.
5. Franck J, Jayaram-Lindstrom N. Pharmacotherapy for alcohol dependence: status of current treatments. *Curr Opin Neurobiol.* 2013;23(4):692-699.
6. Soyka M, Mutschler J. Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine. *Prog Neuropsychopharmacol Biol Psychiatry.* 2016;70:148-161.
7. Wu L, He Y, Jiang B, et al. The effect of a very brief smoking-reduction intervention in smokers who have no intention to quit: study protocol for a randomized controlled trial. *BMC Public Health.* 2015;15:418.
8. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. *Arch Gen Psychiatry.* 2011;68(12):1238-1246.
9. Lee JD, Nunes EV, Jr., Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. *Lancet.* 2018;391(10118):309-318.
10. Jarvis BP, Holtyn AF, Subramaniam S, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. *Addiction.* 2018;113(7):1188-1209.
11. Gorelick DA, Zangen A, George MS. Transcranial magnetic stimulation in the treatment of substance addiction. *Ann N Y Acad Sci.* 2014;1327:79-93.
12. Mishra BR, Praharaj SK, Katshu MZ, Sarkar S, Nizamie SH. Comparison of anticraving efficacy of right and left repetitive transcranial magnetic stimulation in alcohol dependence: a randomized double-blind study. *J Neuropsychiatry Clin Neurosci.* 2015;27(1):e54-59.
13. Herremans SC, Van Schuerbeek P, De Raedt R, et al. The Impact of Accelerated Right Prefrontal High-Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) on Cue-

- Reactivity: An fMRI Study on Craving in Recently Detoxified Alcohol-Dependent Patients. *PLoS One*. 2015;10(8):e0136182.
14. Kravitz AV, Tomasi D, LeBlanc KH, et al. Cortico-striatal circuits: Novel therapeutic targets for substance use disorders. *Brain Res*. 2015;1628(Pt A):186-198.
 15. Prikryl R, Ustohal L, Kucerova HP, et al. Repetitive transcranial magnetic stimulation reduces cigarette consumption in schizophrenia patients. *Prog Neuropsychopharmacol Biol Psychiatry*. 2014;49:30-35.
 16. Protasio MI, da Silva JP, Arias-Carrion O, Nardi AE, Machado S, Cruz MS. Repetitive transcranial magnetic stimulation to treat substance use disorders and compulsive behavior. *CNS Neurol Disord Drug Targets*. 2015;14(3):331-340.
 17. Feil J, Zangen A. Brain stimulation in the study and treatment of addiction. *Neurosci Biobehav Rev*. 2010;34(4):559-574.
 18. Di Chiara G. Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. *Behav Brain Res*. 2002;137(1-2):75-114.
 19. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. *Lancet Psychiatry*. 2016;3(8):760-773.
 20. Volkow ND, Koob GF, McLellan AT. Neurobiologic Advances from the Brain Disease Model of Addiction. *N Engl J Med*. 2016;374(4):363-371.
 21. Volkow ND, Morales M. The Brain on Drugs: From Reward to Addiction. *Cell*. 2015;162(4):712-725.
 22. Volkow ND, Wang GJ, Fowler JS, Tomasi D. Addiction circuitry in the human brain. *Annu Rev Pharmacol Toxicol*. 2012;52:321-336.
 23. Fitzgerald PB, Fountain S, Daskalakis ZJ. A comprehensive review of the effects of rTMS on motor cortical excitability and inhibition. *Clin Neurophysiol*. 2006;117(12):2584-2596.
 24. Hoogendam JM, Ramakers GM, Di Lazzaro V. Physiology of repetitive transcranial magnetic stimulation of the human brain. *Brain Stimul*. 2010;3(2):95-118.
 25. Barr MS, Farzan F, Wing VC, George TP, Fitzgerald PB, Daskalakis ZJ. Repetitive transcranial magnetic stimulation and drug addiction. *Int Rev Psychiatry*. 2011;23(5):454-466.
 26. Hanlon CA, Dowdle LT, Moss H, Canterberry M, George MS. Mobilization of Medial and Lateral Frontal-Striatal Circuits in Cocaine Users and Controls: An Interleaved TMS/BOLD Functional Connectivity Study. *Neuropsychopharmacology*. 2016;41(13):3032-3041.
 27. Hanlon CA, Kearney-Karnos T, Dowdle LT, et al. Developing Repetitive Transcranial Magnetic Stimulation (rTMS) as a Treatment Tool for Cocaine Use Disorder: a Series of Six Translational Studies. *Curr Behav Neurosci Rep*. 2017;4(4):341-352.
 28. Li X, Hartwell KJ, Owens M, et al. Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex reduces nicotine cue craving. *Biol Psychiatry*. 2013;73(8):714-720.
 29. Liu T, Li Y, Shen Y, Liu X, Yuan TF. Gender does not matter: Add-on repetitive transcranial magnetic stimulation treatment for female methamphetamine dependents. *Prog Neuropsychopharmacol Biol Psychiatry*. 2018;92:70-75.
 30. Deng ZD, Lisanby SH, Peterchev AV. Electric field depth-focality tradeoff in transcranial magnetic stimulation: simulation comparison of 50 coil designs. *Brain Stimul*. 2013;6(1):1-13.
 31. Levkovitz Y, Isserles M, Padberg F, et al. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. *World Psychiatry*. 2015;14(1):64-73.
 32. Tekin S, Cummings JL. Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. *J Psychosom Res*. 2002;53(2):647-654.
 33. Haber SN, Kim KS, Maily P, Calzavara R. Reward-related cortical inputs define a large striatal region in primates that interface with associative cortical connections, providing a substrate for incentive-based learning. *J Neurosci*. 2006;26(32):8368-8376.

34. Ongur D, Price JL. The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys and humans. *Cereb Cortex*. 2000;10(3):206-219.
35. Leh SE, Ptito A, Chakravarty MM, Strafella AP. Fronto-striatal connections in the human brain: a probabilistic diffusion tractography study. *Neurosci Lett*. 2007;419(2):113-118.
36. de la Monte SM, Kril JJ. Human alcohol-related neuropathology. *Acta Neuropathol*. 2014;127(1):71-90.
37. Bohning DE, Shastri A, Nahas Z, et al. Echoplanar BOLD fMRI of brain activation induced by concurrent transcranial magnetic stimulation. *Invest Radiol*. 1998;33(6):336-340.
38. Dowdle LT, Borckardt JJ, Back SE, et al. Sensitized brain response to acute pain in patients using prescription opiates for chronic pain: A pilot study. *Drug Alcohol Depend*. 2019;200:6-13.
39. Chen R, Classen J, Gerloff C, et al. Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. *Neurology*. 1997;48(5):1398-1403.
40. Pascual-Leone A, Valls-Sole J, Wassermann EM, Hallett M. Responses to rapid-rate transcranial magnetic stimulation of the human motor cortex. *Brain*. 1994;117 (Pt 4):847-858.
41. Bear MF, Malenka RC. Synaptic plasticity: LTP and LTD. *Curr Opin Neurobiol*. 1994;4(3):389-399.
42. Camprodon JA, Martinez-Raga J, Alonso-Alonso M, Shah M, Pascual-Leone A. One session of high frequency repetitive transcranial magnetic stimulation (rTMS) to the right prefrontal cortex transiently reduces cocaine craving. *Drug Alcohol Depend*. 2007;86(1):91-94.
43. Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. *Lancet*. 2018;391(10131):1683-1692.
44. Kearney-Ramos TE, Dowdle LT, Mithoefer G, Devries W, George MS, Hanlon CA. State-Dependent Effects of Ventromedial Prefrontal Cortex Continuous Thetaburst Stimulation on Cocaine Cue Reactivity in Chronic Cocaine Users. *Front Psychiatry*. 2019;10:317.
45. Isserles M, Shalev AY, Roth Y, et al. Effectiveness of deep transcranial magnetic stimulation combined with a brief exposure procedure in post-traumatic stress disorder--a pilot study. *Brain Stimul*. 2013;6(3):377-383.
46. Dinur-Klein L, Dannon P, Hagar A, et al. Smoking cessation induced by deep repetitive transcranial magnetic stimulation of the prefrontal and insular cortices: a prospective, randomized controlled trial. *Eur Psychiatry*. 2014;76(9):742-749.
47. Hanlon CA, Dowdle LT, Henderson JS. Modulating Neural Circuits with Transcranial Magnetic Stimulation: Implications for Addiction Treatment Development. *Pharmacol Rev*. 2018;70(3):661-683.
48. Ekhtiari H, Tavakoli H, Addolorato G, et al. Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: A consensus paper on the present state of the science and the road ahead. *Neurosci Biobehav Rev*. 2019;104:118-140.
49. Hanlon CA, Dowdle LT, Moss H, Canterberry M, George MS. Mobilization of Medial and Lateral Frontal-Striatal Circuits in Cocaine Users and Controls: An Interleaved TMS/BOLD Functional Connectivity Study. *Neuropsychopharmacology*. 2016; 41:3032-3041.
50. Liston C, Chen AC, Zebley BD, et al. Default mode network mechanisms of transcranial magnetic stimulation in depression. *Biol Psychiatry*. 2014;76(7):517-526.
51. Hanlon CA, Dowdle LT, Austelle CW, et al. What goes up, can come down: Novel brain stimulation paradigms may attenuate craving and craving-related neural circuitry in substance dependent individuals. *Brain Res*. 2015. 1628: 199-209.
52. Kearney-Ramos TE, Dowdle LT, Lench DH, et al. Transdiagnostic Effects of Ventromedial Prefrontal Cortex Transcranial Magnetic Stimulation on Cue Reactivity. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2018;3(7):599-609.

53. Addolorato G, Antonelli M, Cocciolillo F, et al. Deep Transcranial Magnetic Stimulation of the Dorsolateral Prefrontal Cortex in Alcohol Use Disorder Patients: Effects on Dopamine Transporter Availability and Alcohol Intake. *Eur Neuropsychopharmacol.* 2017;27(5):450-461.
54. Terraneo A, Leggio L, Saladini M, Ermani M, Bonci A, Gallimberti L. Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: A pilot study. *Eur Neuropsychopharmacol.* 2016;26(1):37-44.
55. Shen Y, Cao X, Tan T, et al. 10-Hz Repetitive Transcranial Magnetic Stimulation of the Left Dorsolateral Prefrontal Cortex Reduces Heroin Cue Craving in Long-Term Addicts. *Biol Psychiatry.* 2016;80(3):e13-14.
56. di Biase L, Falato E, Di Lazzaro V. Transcranial Focused Ultrasound (tFUS) and Transcranial Unfocused Ultrasound (tUS) Neuromodulation: From Theoretical Principles to Stimulation Practices. *Front Neurol.* 2019;10:549.
57. Bowary P, Greenberg BD. Noninvasive Focused Ultrasound for Neuromodulation: A Review. *Psychiatr Clin North Am.* 2018;41(3):505-514.
58. Darrow DP. Focused Ultrasound for Neuromodulation. *Neurotherapeutics.* 2019;16(1):88-99.
59. Sperling SA, Shah BB, Barrett MJ, et al. Focused ultrasound thalamotomy in Parkinson disease: Nonmotor outcomes and quality of life. *Neurology.* 2013;81(14):e1275-e1284.
60. Lipsman N, Schwartz ML, Huang Y, et al. MR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study. *Lancet Neurol.* 2013;12(5):462-468.
61. Martin E, Jeanmonod D, Morel A, Zadicario E, Weisen B. High-intensity focused ultrasound for noninvasive functional neurosurgery. *Ann Neurol.* 2009;66(6):858-861.
62. Brown MR, Farquhar-Smith P, Williams JE, et al. The use of high-intensity focused ultrasound as a novel treatment for painful conditions—a description and narrative review of the literature. *Br J Anaesth.* 2015;115(4):520-530.
63. Liberman B, Gianfelice D, Inbar Y, et al. Pain palliation in patients with bone metastases using MR-guided focused ultrasound surgery: a multicenter study. *Ann Surg Oncol.* 2009;16(1):140-146.
64. Mehic E, Xu JM, Caler CJ, Cousin NK, Moritz CT, Mourad PD. Increased anatomical specificity of neuromodulation via modulated focused ultrasound. *PLoS One.* 2014;9(2):e86939.
65. Robertson JL, Cox BT, Jans J, Treeby BE. Accurate simulation of transcranial ultrasound propagation for ultrasonic neuromodulation and stimulation. *J Acoust Soc Am.* 2017;141(3):1726.
66. Yoo SS, Bystritsky A, Lee JH, et al. Focused ultrasound modulates region-specific brain activity. *Neuroimage.* 2011;56(3):1267-1275.
67. Rezaayat E, Toostani IG. A Review on Brain Stimulation Using Low Intensity Focused Ultrasound. *Basic Clin Neurosci.* 2016;7(3):187-194.
68. Lipsman N, Meng Y, Bethune AJ, et al. Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound. *Nat Commun.* 2018;9(1):2336.
69. Lee W, Kim HC, Jung Y, et al. Transcranial focused ultrasound stimulation of human primary visual cortex. *Sci Rep.* 2016;6:34026.
70. Hardesty DE, Sackeim HA. Deep brain stimulation in movement and psychiatric disorders. *Biol Psychiatry.* 2007;61(7):831-835.
71. Alonso P, Cuadras D, Gabriels L, et al. Deep Brain Stimulation for Obsessive-Compulsive Disorder: A Meta-Analysis of Treatment Outcome and Predictors of Response. *PLoS One.* 2015;10(7):e0133591.
72. de Haan S, Rietveld E, Stokhof M, Denys D. Effects of Deep Brain Stimulation on the Lived Experience of Obsessive-Compulsive Disorder Patients: In-Depth Interviews with 18 Patients. *PLoS One.* 2015;10(8):e0135524.

73. Denys D, Mantione M, Figeet M, et al. Deep brain stimulation of the nucleus accumbens for treatment-refractory obsessive-compulsive disorder. *Arch Gen Psychiatry*. 2010;67(10):1061-1068.
74. Dougherty DD, Rezai AR, Carpenter LL, et al. A Randomized Sham-Controlled Trial of Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Chronic Treatment-Resistant Depression. *Biol Psychiatry*. 2015;78(4):240-248.
75. Greenberg BD, Gabriels LA, Malone DA, Jr., et al. Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. *Mol Psychiatry*. 2010;15(1):64-79.
76. Greenberg BD, Malone DA, Friehs GM, et al. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. *Neuropsychopharmacology*. 2006;31(11):2384-2393.
77. Hamani C, Andrade D, Hodaie M, Wennberg R, Lozano A. Deep brain stimulation for the treatment of epilepsy. *Int J Neural Syst*. 2009;19(3):213-226.
78. Houeto JL, Karachi C, Mallet L, et al. Tourette's syndrome and deep brain stimulation. *J Neurol Neurosurg Psychiatry*. 2005;76(7):992-995.
79. Laxton AW, Tang-Wai DF, McAndrews MP, et al. A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. *Ann Neurol*. 2010;68(4):521-534.
80. Lipsman N, Woodside B, Lozano AM. Evaluating the potential of deep brain stimulation for treatment-resistant anorexia nervosa. *Handb Clin Neurol*. 2013;116:271-276.
81. Lipsman N, Woodside DB, Giacobbe P, Lozano AM. Neurosurgical treatment of anorexia nervosa: review of the literature from leucotomy to deep brain stimulation. *Eur Eat Disord Rev*. 2013;21(6):428-435.
82. Lozano AM, Fosdick L, Chakravarty MM, et al. A Phase II Study of Fornix Deep Brain Stimulation in Mild Alzheimer's Disease. *J Alzheimers Dis*. 2016;54(2):777-787.
83. Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. *Neuron*. 2005;45(5):651-650.
84. Rezai AR, Krishna V, Bogner J, et al. Letter: Feasibility of Nucleus Accumbens Deep Brain Stimulation for Morbid, Treatment-Refractory Obesity. *Neurosurgery*. 2018;82(5):E136-E137.
85. Rezai AR, Sederberg PB, Bogner J, et al. Improved Function After Deep Brain Stimulation for Chronic, Severe Traumatic Brain Injury. *Neurosurgery*. 2016;79(2):204-211.
86. Whiting DM, Tomycz ND, Bailes J, et al. Lateral hypothalamic area deep brain stimulation for refractory obesity: a pilot study with preliminary data on safety, body weight, and energy metabolism. *J Neurosurg*. 2013;119(1):56-63.
87. Falowski SM. Deep Brain Stimulation for Chronic Pain. *Curr Pain Headache Rep*. 2015;19(7):27.
88. Zhou H, Xu J, Jiang J. Deep brain stimulation of nucleus accumbens on heroin-seeking behaviors: a case report. *Biol Psychiatry*. 2011;69(11):e41-42.
89. Kuhn J, Moller M, Treppmann JF, et al. Deep brain stimulation of the nucleus accumbens and its usefulness in severe opioid addiction. *Mol Psychiatry*. 2014;19(2):145-146.
90. Muller UJ, Sturm V, Voges J, et al. Nucleus Accumbens Deep Brain Stimulation for Alcohol Addiction - Safety and Clinical Long-term Results of a Pilot Trial. *Pharmacopsychiatry*. 2016;49(4):170-173.
91. Grant JE, Odlaug BL, Chamberlain SR. Neurocognitive response to deep brain stimulation for obsessive-compulsive disorder: a case report. *Am J Psychiatry*. 2011;168(12):1338-1339.
92. Kuhn J, Lenartz D, Mai JK, et al. Deep brain stimulation of the nucleus accumbens and the internal capsule in therapeutically refractory Tourette-syndrome. *J Neurol*. 2007;254(7):963-965.
93. Sachdev PS, Cannon E, Coyne TJ, Silburn P. Bilateral deep brain stimulation of the nucleus accumbens for comorbid obsessive compulsive disorder and Tourette's syndrome. *BMJ Case Rep*. 2012;2012.

94. Mantione M, van de Brink W, Schuurman PR, Denys D. Smoking cessation and weight loss after chronic deep brain stimulation of the nucleus accumbens: therapeutic and research implications: case report. *Neurosurgery*. 2010;66(1):E218; discussion E218.
95. Benwell CS, Learmonth G, Miniussi C, Harvey M, Thut G. Non-linear effects of transcranial direct current stimulation as a function of individual baseline performance: Evidence from biparietal tDCS influence on lateralized attention bias. *Cortex*. 2015;69:152-165.
96. Thair H, Holloway AL, Newport R, Smith AD. Transcranial Direct Current Stimulation (tDCS): A Beginner's Guide for Design and Implementation. *Front Neurosci*. 2017;11:641.
97. Nitsche MA, Paulus W. Sustained excitability elevations induced by transcranial DC motor cortex stimulation in humans. *Neurology*. 2001;57(10):1899-1901.
98. Razza LB, Palumbo P, Moffa AH, et al. A systematic review and meta-analysis on the effects of transcranial direct current stimulation in depressive episodes. *Depress Anxiety*. 2020.
99. Stein DJ, Fernandes Medeiros L, Caumo W, Torres IL. Transcranial Direct Current Stimulation in Patients with Anxiety: Current Perspectives. *Neuropsychiatr Dis Treat*. 2020;16:161-169.
100. Kekic M, Boysen E, Campbell IC, Schmidt U. A systematic review of the clinical efficacy of transcranial direct current stimulation (tDCS) in psychiatric disorders. *J Psychiatr Res*. 2016;74:70-86.
101. Luigjes J, Segrave R, de Joode N, Figuee M, Denys D. Efficacy of Invasive and Non-Invasive Brain Modulation Interventions for Addiction. *Neuropsychol Rev*. 2019;29(1):116-138.
102. Brunoni AR, Moffa AH, Fregni F, et al. Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data. *Br J Psychiatry*. 2016;208(6):522-531.
103. Berryhill ME, Peterson DJ, Jones KT, Stephen JA. Hits and misses: leveraging tDCS to advance cognitive research. *Front Psychol*. 2014;5:800.
104. Li LM, Uehara K, Hanakawa T. The contribution of interindividual factors to variability of response in transcranial direct current stimulation studies. *Front Cell Neurosci*. 2015;9:181.
105. Herrera-Melendez AL, Bajbouj M, et al. S. Application of Transcranial Direct Current Stimulation in Psychiatry. *Neuro-psychobiology*. 2019:1-12.
106. Fregni F, Liguori P, Fecteau S, Nitsche MA, Pascual-Leone A, Boggio PS. Cortical stimulation of the prefrontal cortex with transcranial direct current stimulation reduces cue-provoked smoking craving: a randomized, sham-controlled study. *J Clin Psychiatry*. 2008;69(1):32-40.
107. Boggio PS, Liguori P, Sultani N, Rezende L, Fecteau S, Fregni F. Cumulative priming effects of cortical stimulation on smoking cue-induced craving. *Neurosci Lett*. 2009;463(1):82-86.
108. Boggio PS, Sultani N, Fecteau S, et al. Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: a double-blind, sham-controlled study. *Drug Alcohol Depend*. 2008;92(1-3):55-60.
109. da Silva MC, Conti CL, Klauss J, et al. Behavioral effects of transcranial direct current stimulation (tDCS) induced dorsolateral prefrontal cortex plasticity in alcohol dependence. *J Physiol Paris*. 2013;107(6):493-502.
110. Batista EK, Klauss J, Fregni F, Nitsche MA, Nakamura-Palacios EM. A Randomized Placebo-Controlled Trial of Targeted Prefrontal Cortex Modulation with Bilateral tDCS in Patients with Crack-Cocaine Dependence. *Int J Neuropsychopharmacol*. 2015;18(12).
111. Boggio PS, Zaghi S, Villani AB, Fecteau S, Pascual-Leone A, Fregni F. Modulation of risk-taking in marijuana users by transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (DLPFC). *Drug Alcohol Depend*. 2010;112(3):220-225.
112. Coffman BA, Clark VP, Parasuraman R. Battery powered thought: enhancement of attention, learning, and memory in healthy adults using transcranial direct current stimulation. *Neuroimage*. 2014;85 Pt 3:895-908.
113. Parasuraman R, McKinley RA. Using noninvasive brain stimulation to accelerate learning and enhance human performance. *Hum Factors*. 2014;56(5):816-824.

114. Hofmeister M, Memedovich A, Brown S, et al. Effectiveness of Neurostimulation Technologies for the Management of Chronic Pain: A Systematic Review. *Neuromodulation*. 2019.
115. Brief Summary of Safety Information for the VNS Therapy® System J, LivaNova). .
116. Bauer S, Baier H, Baumgartner C, et al. Transcutaneous Vagus Nerve Stimulation (tVNS) for Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial (cMPsE02). *Brain Stimul*. 2016;9(3):356-363.
117. Mwamburi M, Tenaglia AT, Leibler EJ, Staats PS. Review of evidence on noninvasive vagus nerve stimulation for treatment of migraine: efficacy, safety, and implications. *Am J Manag Care*. 2018;24(24 Suppl):S507-S516.
118. Garcia RG, Lin RL, Lee J, et al. Modulation of brainstem activity and connectivity by respiratory-gated auricular vagal afferent nerve stimulation in migraine patients. *Pain*. 2017;158(8):1461-1472.
119. Liu H, Liu Y, Yu J, et al. Vagus nerve stimulation inhibits heroin-seeking behavior induced by heroin priming or heroin-associated cues in rats. *Neurosci Lett*. 2011;494(1):70-74.
120. Childs JE, DeLeon J, Nickel E, Kroener S. Vagus nerve stimulation reduces cocaine seeking and alters plasticity in the extinction network. *Learn Mem*. 2011;24(1):35-42.
121. Kaniusas E, Kampusch S, Tittgemeyer M, et al. Current Directions in the Auricular Vagus Nerve Stimulation I - A Physiological Perspective. *Front Neurosci*. 2019;13:854.
122. Wu C, Liu P, Fu H, et al. Transcutaneous auricular vagus nerve stimulation in treating major depressive disorder: A systematic review and meta-analysis. *Medicine (Baltimore)*. 2018;97(52):e13845.
123. Liu CH, Yang MH, Zhang GZ, et al. Neural networks and the anti-inflammatory effect of transcutaneous auricular vagus nerve stimulation in depression. *J Neuroinflammation*. 2020;17(1):54.
124. Food and Drug Administration. (2017). De Novo Classification Request for NSS-2 Bridge. Retrieved from www.accessdata.fda.gov/cdrh_docs/reviews/DEN170018.pdf.
125. Miranda A, Taca A. Neuromodulation with percutaneous electrical nerve field stimulation is associated with reduction in signs and symptoms of opioid withdrawal: a multisite, retrospective assessment. *Am J Drug Alcohol Abuse*. 2018;44(1):56-63.
126. Food and Drug Administration. (2019). FDA permits marketing of first medical device for treatment of ADHD. Retrieved from <https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-medical-device-treatment-adhd>.
127. McGough JJ, Sturm A, Cowen J, et al. Double-Blind, Sham-Controlled, Pilot Study of Trigeminal Nerve Stimulation for Attention-Deficit/Hyperactivity Disorder. *J Am Acad Child Adolesc Psychiatry*. 2019;58(4):403-411 e403.
128. Jakobs M, Schuh-Hofer S, Unterberg A, Ahmadi R. Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain. *J Vis Exp*. 2017(123).
129. Slaughter SJ, Nashef L. An audit of external trigeminal nerve stimulation (eTNS) in epilepsy. *Seizure*. 2017;52:60-62.
130. Generoso MB, Taiar IT, Garrocini LP, et al. Effect of a 10-day transcutaneous trigeminal nerve stimulation (TNS) protocol for depression amelioration: A randomized, double blind, and sham-controlled phase II clinical trial. *Epilepsy Behav*. 2019;95:39-42.
131. Schiffer F, Johnston AL, Ravichandran C, et al. Psychological benefits 2 and 4 weeks after a single treatment with near infrared light to the forehead: a pilot study of 10 patients with major depression and anxiety. *Behav Brain Funct*. 2009;5:46.
132. Salehpour F, Rasta SH. The potential of transcranial photobiomodulation therapy for treatment of major depressive disorder. *Rev Neurosci*. 2017;28(4):441-453.
133. Salehpour F, Ahmadian N, Rasta SH, Farhoudi M, Karimi P, Sadigh-Eteghad S. Transcranial low-level laser therapy improves brain mitochondrial function and cognitive impairment in D-galactose-induced aging mice. *Neurobiol Aging*. 2017;58:140-150.

134. Michalikova S, Ennaceur A, van Rensburg R, Chazot PL. Emotional responses and memory performance of middle-aged CD1 mice in a 3D maze: effects of low infrared light. *Neurobiol Learn Mem.* 2008;89(4):480-488.
135. Zalewska-Kaszubska J, Obzejta D. Use of low-energy laser as adjunct treatment of alcohol addiction. *Lasers Med Sci.* 2004;19(2):100-104.
136. Sliedrecht W, de Waart R, Witkiewitz K, Roozen HG. Alcohol use disorder relapse factors: A systematic review. *Psychiatry Res.* 2019;278:97-115.
137. Sayette MA. The Role of Craving in Substance Use Disorders: Theoretical and Methodological Issues. *Annu Rev Clin Psychol.* 2016;12:407-433.
138. Bari A, DiCesare J, Babayan D, Runcie M, Sparks H, Wilson B. Neuromodulation for substance addiction in human subjects: A review. *Neurosci Biobehav Rev.* 2018;95:33-43.
139. Rachid F. Neurostimulation techniques in the treatment of nicotine dependence: A review. *Am J Addict.* 2016;25(6):436-451.
140. Ward HB, Mosquera MJ, Suzuki J, Mariano TY. A Systematic Review of Noninvasive Brain Stimulation for Opioid Use Disorder. *Neuromodulation.* 2020;23(3):301-311.
141. Mahoney JJ, Marshalek PJ, Rezai AR, Lander LR, Berry JH, Haut MW. A case report illustrating the effects of repetitive transcranial magnetic stimulation on cue-induced craving in an individual with opioid and cocaine use disorder. *Exp Clin Psychopharmacol.* 2020;28(1):1-5.
142. Mahoney JJ, Haut, M, Hodder, S, Zheng, W, Lander, L, Berry, J, Brandmeir, N, Ranjan, M, Finomore, V, Wang, G, Tomasi, D, Shokri-Kojori E., Rezai, A. Deep Brain Stimulation of the Nucleus Accumbens/Ventral Capsule for Co-Occurring Opioid and Benzodiazepine Use Disorder. Oral Presentation at the College on Problems of Drug Dependence Virtual Meeting, June 2020.

Research Highlights:

- Several forms of neuromodulation are being investigated for SUD treatment.
- Neuromodulation shows promise in reducing SUD risk factors for relapse (e.g. substance craving).
- Further research investigating neuromodulation warrants consideration for SUD treatment.